← All trials
NCT00075816
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2004
- Primary completion
- Apr 1, 2013
- Completion date
- Apr 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 551
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical College of WisconsinLead sponsor
- Center for International Blood and Marrow Transplant ResearchStudy director
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Cancer Institute (NCI)Collaborator
- National Marrow Donor ProgramCollaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.